<DOC>
	<DOCNO>NCT02949908</DOCNO>
	<brief_summary>This prospective , multicenter , open label , uncontrolled , non-interventional , single arm study measure treatment satisfaction relapse remit MS ( RRMS ) subject Rebif discontinue initial first-line treatment.This study regional study 3 participate country : Belgium , Netherlands Switzerland</brief_summary>
	<brief_title>MEasuring Satisfaction Treatment With REbif After Initial Treatment MS ( MESTRE-MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male female , 18 65 year age ( inclusive ) , time informed consent Subjects diagnose RRMS accord McDonald criterion 2010 Subject discontinue treatment dimethyl fumarate ( Tecfidera ) , teriflunomide ( Aubagio ) , glatiramer acetate ( Copaxone® ) , intramuscular IFNβ1a ( Avonex® ) , pegylated interferon ( Plegridy® ) , subcutaneous IFNβ1b ( Betaferon® ) fingolimod ( Gilenya® ) within 6 month prior Visit 1 Currently treat Rebif use RebiSmart 2.0 , maximum 6 month prior Visit 1 Subjects score Expanded Disability Status Scale ( EDSS ) 0 5.0 inclusive Subjects willing able give inform consent . Subjects know planned surgical procedure time inform consent prevent adherence treatment Rebif RebiSmart 2.0 Subjects diagnose primary progressive , secondary progressive , progressive relapse MS pregnant lactating , plan become pregnant subject In opinion Investigator significant renal hepatic impairment significant disease ( e.g. , cognitive visual impairment ) would compromise adherence completion study Reports reason he/she complete 1 year study Subjects history hypersensitivity natural recombinant interferon , component formulation Subjects contraindicate treatment subcutaneous IFNβ1a therapy per summary product characteristic currently approve specific country product information Subjects factor opinion Investigator would make subject unsuitable participation study Subjects significant psychiatric symptom , opinion Investigator , would impact patient ability comply treatment recommendation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Rebif</keyword>
	<keyword>Treatment Satisfaction Questionnaire Medication Version II</keyword>
	<keyword>Multiple Sclerosis International Quality Life Questionnaire</keyword>
</DOC>